- Home
- PRVA vs HCM Comparison
PRVA vs HCM Comparison
Compare PRVA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRVA
- HCM
- Stock Information
- Founded
- PRVA 2007
- HCM 2000
- Country
- PRVA United States
- HCM Hong Kong
- Employees
- PRVA N/A
- HCM N/A
- Industry
- PRVA Retail: Computer Software & Peripheral Equipment
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PRVA Technology
- HCM Health Care
- Exchange
- PRVA Nasdaq
- HCM Nasdaq
- Market Cap
- PRVA 2.8B
- HCM 2.6B
- IPO Year
- PRVA 2021
- HCM N/A
- Fundamental
- Price
- PRVA $22.79
- HCM $17.93
- Analyst Decision
- PRVA Strong Buy
- HCM
- Analyst Count
- PRVA 14
- HCM 0
- Target Price
- PRVA $28.79
- HCM N/A
- AVG Volume (30 Days)
- PRVA 722.8K
- HCM 55.8K
- Earning Date
- PRVA 11-06-2025
- HCM 08-07-2025
- Dividend Yield
- PRVA N/A
- HCM N/A
- EPS Growth
- PRVA N/A
- HCM N/A
- EPS
- PRVA 0.11
- HCM 0.53
- Revenue
- PRVA $1,900,071,000.00
- HCM $602,197,000.00
- Revenue This Year
- PRVA $95.64
- HCM $2.73
- Revenue Next Year
- PRVA $10.27
- HCM $17.33
- P/E Ratio
- PRVA $207.39
- HCM $6.48
- Revenue Growth
- PRVA 12.05
- HCM N/A
- 52 Week Low
- PRVA $16.47
- HCM $11.51
- 52 Week High
- PRVA $26.09
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- PRVA 58.81
- HCM 65.46
- Support Level
- PRVA $22.49
- HCM $15.51
- Resistance Level
- PRVA $23.90
- HCM $16.28
- Average True Range (ATR)
- PRVA 0.53
- HCM 0.33
- MACD
- PRVA 0.01
- HCM 0.24
- Stochastic Oscillator
- PRVA 62.75
- HCM 90.00
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.